Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors.
Source: Motley Fool
2026-05-04 17:49:27 ET
Julie Rubinstein, President and Chief Operating Officer of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) , reported the exercise of 14,707 options and immediate sale of 19,037 shares of common stock on April 27, 2026 for a total value of approximately $271,000, as disclosed in the SEC Form 4 filing .
Transaction and post-transaction values based on SEC Form 4 weighted average purchase price ($14.23).
Adaptive Biotechnologies Corporation is a biotechnology company specializing in immune-driven diagnostics and therapeutic platforms, with a market presence in both research and clinical settings.
Adaptive Biotechnologies Corporation
NASDAQ: ADPT
ADPT Trading
-2.31% G/L:
$16.92 Last:
899,877 Volume:
$17.90 Open:
ADPT Latest News
ADPT Stock Data
$2,393,790,148
142,894,616
2.45%
99
N/A
Biotechnology & Life Sciences
Healthcare
US
Seattle
